Chinook Therapeutics Stock Price, News & Analysis
Company Description
Chinook Therapeutics (NASDAQ: KDNY) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $2.7B.
KDNY stock has declined 100.0% over the past year.
This page provides a comprehensive overview of KDNY stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Chinook Therapeutics (KDNY) stock. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $2.7B, KDNY is classified as a mid-cap stock with approximately 71.8M shares outstanding.
Latest News
Chinook Therapeutics has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include clinical trial, conferences, partnership, earnings, management. View all KDNY news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
KDNY Company Profile & Sector Positioning
Chinook Therapeutics (KDNY) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing KDNY often look at related companies in the same sector, including Ultragenyx Pharm (RARE), Immunovant Inc (IMVT), Viking Therapeutics Inc (VKTX), Amicus Therapeut (FOLD), and Scholar Rock Holding (SRRK). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate KDNY's relative position within its industry.